Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast scheduled for Wednesday, November 13, 2024, at 8:30 AM Eastern Time. The webcast will review the company's third-quarter 2024 financial results and provide corporate updates. The company plans to file its Q3 2024 Earnings Report on Form 10-Q for the quarter ended September 30, 2024. A replay of the webcast will be available on Jaguar's investor relations website section.
Jaguar Health (NASDAQ:JAGX) ha annunciato un prossimo webcast per gli investitori previsto per mercoledì 13 novembre 2024, alle 8:30 ora orientale. Il webcast esaminerà i risultati finanziari del terzo trimestre 2024 dell'azienda e fornirà aggiornamenti aziendali. L'azienda prevede di presentare il suo Rapporto sugli Utili del Q3 2024 tramite il modulo 10-Q per il trimestre conclusosi il 30 settembre 2024. Una registrazione del webcast sarà disponibile nella sezione dedicata alle relazioni con gli investitori del sito web di Jaguar.
Jaguar Health (NASDAQ:JAGX) ha anunciado un próximo webcast para inversores programado para el miércoles 13 de noviembre de 2024, a las 8:30 AM hora del Este. El webcast revisará los resultados financieros del tercer trimestre de 2024 de la empresa y proporcionará actualizaciones corporativas. La empresa planea presentar su Informe de Ganancias del Q3 2024 en el Formulario 10-Q para el trimestre que finalizó el 30 de septiembre de 2024. Una repetición del webcast estará disponible en la sección de relaciones con inversores del sitio web de Jaguar.
재규어 헬스(JAGX, NASDAQ)가 2024년 11월 13일 수요일 동부 표준시 기준 오전 8시 30분에 예정된 투자자 웹캐스트를 발표했습니다. 이 웹캐스트에서는 회사의 2024년 3분기 재무 결과를 검토하고 기업 업데이트를 제공합니다. 회사는 2024년 9월 30일로 종료된 분기 수익 보고서를 양식 10-Q로 제출할 계획입니다. 웹캐스트의 재생본은 재규어의 투자자 관계 웹사이트 섹션에서 확인할 수 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé un prochain webcast pour les investisseurs prévu pour le mercredi 13 novembre 2024, à 8h30, heure de l'Est. Le webcast examinera les résultats financiers du troisième trimestre 2024 de l'entreprise et fournira des mises à jour sur la société. L'entreprise prévoit de soumettre son Rapport sur les résultats du T3 2024 sous le Formulaire 10-Q pour le trimestre clos le 30 septembre 2024. Un enregistrement du webcast sera disponible dans la section des relations avec les investisseurs du site Web de Jaguar.
Jaguar Health (NASDAQ:JAGX) hat ein bevorstehendes Investoren-Webcast angekündigt, das für Mittwoch, den 13. November 2024, um 8:30 Uhr Eastern Time geplant ist. Das Webcast wird die finanziellen Ergebnisse des dritten Quartals 2024 des Unternehmens überprüfen und Unternehmensupdates bereitstellen. Das Unternehmen plant, seinen Q3 2024 Earnings Report im Formular 10-Q für das am 30. September 2024 endende Quartal einzureichen. Eine Wiederholung des Webcasts wird im Bereich Investor Relations der Website von Jaguar verfügbar sein.
- None.
- None.
Click here to register for investor webcast
Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024
SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate updates.
Participation Instructions for Webcast
When: Wednesday, November 13, 2024 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will conduct an investor webcast on November 13, 2024. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified, and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
When is Jaguar Health (JAGX) releasing Q3 2024 earnings?
What time is Jaguar Health's (JAGX) Q3 2024 earnings webcast?
Where can I access the replay of Jaguar Health's (JAGX) Q3 2024 earnings webcast?
